Dr. Henry Chi Hang Fung to Oversee Bone Marrow Transplant Services at Fox Chase Cancer Center

A well-known leader in the field of blood diseases and bone marrow transplantation, Dr. Fung has joined Fox Chase Cancer Center. and will also be Director of the Temple University Hospital Bone Marrow Transplant Program.
Read more »

Fox Chase’s Paul F. Engstrom, MD, to Receive Association of Community Cancer Centers Annual Clinical Care Achievement Award

Engstrom has devoted his professional and academic career to improving cancer prevention and early detection research and service.
Read more »

Richard I. Fisher, MD, Named President and CEO of Fox Chase Cancer Center

Since his arrival Fisher has demonstrated adroit and sure-handed leadership and administrative ability, working closely with leaders at Fox Chase and across Temple Health.
Read more »

The Hematology/Oncology department provides quality diagnosis, treatment, and care for patients with cancer.

Hematology/Oncology Staff List

Paul F. Engstrom, MD, Professor and Chairman, Hematology/Oncology

David Eli Adelberg, MD, Attending Physician, Hematology/Oncology, AtlantiCare Cancer Institute

Igor Astsaturov MD, PhD, Assistant Professor, Gastrointestinal Oncology

Stefan Barta MD, MS, MRCP (UK), Assistant Professor, Hematologic Oncology

Jessica Bauman, MD, Assistant Professor, Hematology/Oncology

Marijo Bilusic, MD, PhD, Assistant Professor, Genitourinary Oncology

Hossein Borghaei, DO, Chief, Thoracic Oncology
Director, Lung Cancer Risk Assessment

Robert Carlson, MD, Attending Physician, Hematology/Oncology

Jonathan D. Cheng, MD, Attending Physician, Gastrointestinal Oncology

Steven J. Cohen MD, Chief, Gastrointestinal Oncology

Crystal S. Denlinger, MD, Assistant Professor, Gastrointestinal Oncology

Efrat Dotan, MD, Attending Physician, Breast Cancer, Gastrointestinal Oncology

Scot W. Ebbinghaus, MD, Attending Physician, Thoracic Oncology

Wafik El-Deiry, MD, PhD, FACP, Professor, Gastrointestinal Oncology,
Deputy Cancer Center Director for Translational Research

Richard I. Fisher, MD, President and CEO, Fox Chase Cancer Center
Attending Physician,
Hematologic Oncology

Henry Chi Hang Fung, MD, FRCPE, Director, Bone Marrow Transplant Program,
Director, Hematologic Oncology Treatment

Vijaykumar K. Gandhi, MD, Adjunct Professor, Hematology/Oncology, AtlantiCare Cancer Institute

Daniel M. Geynisman, MD, Attending Physician, Genitourinary Oncology

Lori Goldstein, MD, Director, The Naomi and Phil Lippincott Breast Evaluation Center

Gary R. Hudes, MD, Attending Physician, Genitourinary Oncology

Angela Jain, MD, Assistant Professor, Gynecologic Oncology

Nadia Khan, MD, Assistant Professor, Hematologic Oncology

Patricia L. Kropf, MD, Assistant Director, Bone Marrow Transplant Program

Gregory Michael Lubiniecki, MD, Attending Physician, Thoracic Oncology

Lainie P. Martin, MD, Chief, GYN Hematology Oncology

Mary Ellen Martin, MD, FACP, Assistant Director, Bone Marrow Transplant Program

Ranee Mehra, MD, Chief, Head & Neck Hematology Oncology

Michael M. Millenson, MD, Director, Hematology Service

Juhi Mittal, MD, Assistant Professor, GI Malignancies

Sujana Movva, MD, Assistant Professor, Sarcoma & Melanoma

Anthony J. Olszanski, MD, RPh, Director, Early Clinical Drug Development, Clinical Trials,
Director, Phase I Program, Clinical Trials,
Director, Clinical Pharmacology

Aruna Padmanabhan, MD, Associate Professor, Breast Malignancies

Alvaro Pereira-Rico, MD, Associate Professor, GU Malignancies

Elizabeth Plimack, MD, MS, Associate Professor, Genitourinary Oncology

Vijay Sandilya, MD, Medical Director, Department of Medical Oncology, AtlantiCare Cancer Care Institute,
Attending Physician, AtlantiCare

Deric C. Savior, MD, Assistant Professor, Thoracic Oncology

Jennifer Shih Winn, MD, MS, Attending Physician, Breast Cancer Treatment

Joseph Treat, MD, Attending Physician, Thoracic Oncology

Namrata (Neena) Vijayvergia, MD

Margaret von Mehren, MD , Physician Director, Clinical Trials Office

Yu-Ning Wong, MD, MSCE, Associate Professor, Genitourinary Oncology

Matthew R. Zibelman, MD, Clinical Instructor


Pain and Palliative Care

Marcin Chwistek, MD, Interim Director, Pain and Palliative Care Program

Advanced Practice Clinicians



Traditional chemotherapy and new clinical trials provide our oncologists with access to a tremendous range of new anticancer treatments, including medicines and combinations of medicines.

"Personalized" treatment involves identifying characteristics of individual patients' tumors in order to determine their responsiveness to specific chemotherapy drugs. The ultimate goal of such analysis is to determine which tumors are sensitive to a given drug and equally important, which tumors are resistant to specific drugs.

A similar approach has already benefited the Fox Chase Gastrointestinal Cancer program, where patients with metastatic colorectal cancer are routinely screened for mutations in the K-RAS gene to determine the most effective drug treatment. Fox Chase's Clinical Molecular Genetics Laboratory has been conducting this test since 2007.

This focus on personalized medicine is just another example of Fox Chase's leadership in bringing state-of-the-art research directly to the bedside and delivering expert and compassionate care with the goal of improving patient outcomes.